# IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)

> **NCT03055806** · PHASE2 · COMPLETED · sponsor: **Ixchelsis Limited** · enrollment: 239 (actual)

## Conditions studied

- Premature Ejaculation

## Interventions

- **DRUG:** IX-01 400 mg
- **DRUG:** Placebo
- **DRUG:** IX-01 800 mg
- **DRUG:** IX-01 1200 mg

## Key facts

- **NCT ID:** NCT03055806
- **Lead sponsor:** Ixchelsis Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-28
- **Primary completion:** 2017-11-17
- **Final completion:** 2017-12-06
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2019-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03055806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03055806, "IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03055806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*